Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Insight Molecular Diagnostics (NASDAQ:IMDX) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$518.0k (up 398% from 2Q 2024).
• Net loss: US$9.74m (loss widened by 112% from 2Q 2024).
• US$0.30 loss per share.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Insight Molecular Diagnostics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 77%. Earnings per share (EPS) missed analyst estimates by 30%.

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.5% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Insight Molecular Diagnostics (at least 2 which shouldn't be ignored), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.